PDGFRalpha (550-end, V561D), active

10 µg of active PDGFRα. N-terminal 6His-tagged recombinant, human PDGFRα amino acids 550 – end, containing the V561D mutation.

Catalog #: 14-735


Biological Information
Background Information:
PDGFRα (Platelet-Derived Growth Factor Receptor Alpha) is a transmembrane receptor protein that belongs to the family of receptor tyrosine kinases. It is involved in a variety of cellular processes, including cell growth, differentiation, migration, and survival. PDGFRα is expressed in a variety of tissues and cell types, including fibroblasts, smooth muscle cells, and certain types of cancer cells. Aberrant activation of PDGFRα has been implicated in several diseases, including cancer, fibrotic disorders, and vascular diseases. PDGFRα mutations, amplifications, and overexpression have been found in various types of cancer, making it a potential target for cancer therapy. Additionally, drugs that target PDGFRα have been approved for the treatment of certain types of cancer, such as gastrointestinal stromal tumors (GIST) and chronic myelomonocytic leukemia (CMML).
Target Class:
Receptor Typosine Kinase (RTK): Growth Factor Receptor
Accession Number:
Target Name:
Target Aliases:
PDGFRA, CD140a, PDGF-R-alpha, MGC74795, PDGFR2, Rhe-PDGFRA, CD140A
Target Species:
Product Type:
Drug Discovery & Development
Storage Conditions:
6 months at -70°C
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.


14-735x Datasheet

View Document